farshad guirakhoo geovax labs inc profile  biography  bloomberg feedback farshad guirakhoo chief scientific office geovax labs inc career history chief scientific office geovax labs inc present senior vpresearch  development geovax labs inc  senior director acambis inc former website wwwgeovaxcom corporate information address  lake park drive suite  smyrna ga  united states phone  fax  web url wwwgeovaxcom from the web personal information education universitat wien phd university of tehran masters degree national university of iran bachelors degree biology show more sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data home site map about us media kit contact us help register now why register login  the leading web portal for pharmacy resources news education and careers july   news drug delivery systems drugstores fda final approvals front page healthcare news generic drugs hospital industry internet pharmacy it in healthcare medicare  medicaid overthecounter drugs pharm industry trends and policy pharmaceutical development pharmaceutical industry pharmacy careers pharmacist pharmacy technician pharmacy job board job placement help so you want a job as a pharmacist start your career as apharmacy technician resources boards of pharmacy drug database fda resources pharmacy associations pharmacy journals pharmacy newsletters state associations more education certification courses continuing education disease state management international pharmacy schools live online ce pharmacy schools pharmacy technician training business advertising information  media kit consulting contact us pharmacy marketing marketplace drug manufacturers drug wholesalers automation and robotics compounding supplies medication  supply dispensing systems tablet  capsule counters wholesalers  distributors more pharmacy choice  pharmaceutical news  farshad guirakhoo phd joins geovax as senior vice president research and development  july   pharmacy news article    farshad guirakhoo phd joins geovax as senior vice president research and development atlanta ga marketwired  geovax labs inc otcqb govx a biotechnology company developing human vaccines using its novel platform technology announced today the appointment of farshad guirakhoo phd as senior vice president research and development dr guirakhoo is a worldrenowned virologist and brings more than  years of industry experience in the development of vaccines and monoclonal antibody products to geovax dr guirakhoo is a former executivesenior director of sanofi pasteur as senior vice president research and development dr guirakhoo will play a leading role in the expansion of geovaxs product development pipeline and will be integral to collaborating on the development and implementation of a growth strategy to build upon geovaxs novel platform technology and expertise he will also contribute to the companys ongoing efforts to develop and commercialize its hiv and ebola vaccines we are thrilled that dr guirakhoo will be joining us said harriet robinson phd chief scientific officer at geovax there is substantial work to be done to successfully move our current vaccine programs forward and to build upon our technology platform we are fortunate to have a professional of dr guirakhoos caliber adding his talents to the effort it is a major milestone for the company to have dr guirakhoo joining our scientific team in a leadership role robert mcnally phd geovaxs president and ceo added dr guirakhoo will be a key member of our senior management team his extensive experience in vaccine development will be important to us as we embark on our strategy to accelerate our hiv vaccine candidate to pivotal clinical trials and as we make further progress toward clinical trials for our ebolamarburg vaccines and as we look to geovaxs future nothing is more critical than continuously building our capabilities and collective expertise with experienced scientific minds dr guirakhoos experience and intellectual curiosity will serve us well and i expect he will move quickly in the identification of highvalue areas into which we may expand our product development portfolio we welcome dr guirakhoo and look forward to his contributions i am truly excited to join geovaxs team not only to further accelerate its advanced clinical programs for an hiv vaccine which is the only cost effective way to eradicate this devastating disease especially in developing countries but also utilize its novel platform to develop other vaccines with high medical impact said farshad guirakhoo phd dr guirakhoo has served in senior management and scientific roles within the biotechnology industry with vaxess technologies hookipa biotech sanofi pasteur acambis inc and oravax inc he earned his phd in virology at the medical university of vienna vienna austria holds a msc degree in genetics from the international institute for biophysics and biochemistry of tehran university and a bsc degree in biology from the national university of iran he conducted his postdoctoral training at the medical university of vienna and at the national centers for disease control and prevention cdc division of vectorborne infectious diseases in his scientific career dr guirakhoo has filed over  patent applications and is authorcoauthor of more than  publications including book chapters in peerreviewed journals in  he was named as one of the  most influential people in vaccines about geovax geovax labs inc is a clinicalstage biotechnology company developing human vaccines against infectious diseases using its novel vaccine platform current development programs are focused on vaccines against ebola marburg and human immunodeficiency virus hiv geovax believes its technology and vaccine development expertise is wellsuited for a wide variety of human infectious diseases for which there is an unmet medical need and intends to pursue expansion of its product pipeline geovaxs vaccine platform supports production of noninfectious viruslike particles vlps from the cells of the person receiving the vaccine the production of vlps in the person being vaccinated mimics a natural infection stimulating both the humoral and cellular arms of the immune system to recognize prevent and control the target infection should it appear clinical trials for geovaxs preventive hiv vaccines have been conducted by the nihsupported hiv vaccine trials network hvtn with funding from the national institute of allergy and infectious disease niaid overall geovaxs hiv vaccines in various doses and combinations have been tested in about  humans for more information go to wwwgeovaxcom forwardlooking statements certain statements in this document are forwardlooking statements within the meaning of the private securities litigation reform act these statements are based on managements current expectations and are subject to uncertainty and changes in circumstances actual results may differ materially from those included in these statements due to a variety of factors including whether geovax can develop and manufacture its vaccines with the desired characteristics in a timely manner geovaxs vaccines will be safe for human use geovaxs vaccines will effectively prevent hiv or ebola infection in humans vaccines will receive regulatory approvals necessary to be licensed and marketed geovax raises required capital to complete vaccine development there is development of competitive products that may be more effective or easier to use than geovaxs products geovax will be able to enter into favorable manufacturing and distribution agreements and other factors over which geovax has no control geovax assumes no obligation to update these forwardlooking statements and does not intend to do so more information about these factors is contained in geovaxs filings with the securities and exchange commission including those set forth at risk factors in geovaxs form k contact robert t mcnally phd geovax labs inc  source geovax inc pharmacy news index   drug delivery systems   drugstores   fda final approvals   front page healthcare news   generic drugs   hospital industry   internet pharmacy   it in healthcare   medicare  medicaid   overthecounter drugs   pharm industry trends and policy   pharmaceutical development   pharmaceutical industry live online ce jul  obesity management overview of pharmacotherapy aug  treatment of depression and anxiety in older adults aug  adverse drug events risk reduction  documentation aug  medication use during pregnancy  lactation aug  using barcodes to improve medication safety considerations for pharmacists  technicians click for entire webinar calendar special announcement free membership enjoy drug search industry newsletters and more nursing jobs are you a nurse looking for a job check out the nursing job source your number one choice for nursing jobs websites » rxcareercentercom • rxschoolcom • clubstaffingcom • nursingjobsourcecom • rncom news drug delivery systems drugstores fda final approvals front page healthcare news generic drugs hospital industry internet pharmacy it in healthcare medicare  medicaid overthecounter drugs pharm industry trends and policy pharmaceutical development pharmaceutical industry careers pharmacist pharmacy technician pharmacy job board jobs placement help so you want a job as a pharmacist start your career as apharmacy technician resources boards of pharmacy drug databases fda resources pharmacy associations pharmacy journals pharmacy newsletters state associations more education certification courses continuing education disease state management international pharmacy schools live online ce pharmacy ce pharmacy schools pharmacy tech training business advertising information consulting contact us pharmacy marketing marketplace drug manufacturers drug wholesalers automation and robotics compounding supplies medication  supply   dispensing systems tablet  capsule counters wholesalers  distributors more most popular pharmacy jobs continuing education fda resources drug information pharmacy news disease states pharm tech training copyright   pharmacy choice  all rights reserved terms and conditions  privacy statement  farshad guirakhoo ph d joins geovax inc as senior vice president research and development employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       farshad guirakhoo phd joins geovax inc as senior vice president research and development tweet   pm atlanta gamarketwired  october    geovax labs inc otcqb govx a biotechnology company developing human vaccines using its novel platform technology announced today the appointment of farshad guirakhoo phd as senior vice president research and development dr guirakhoo is a worldrenowned virologist and brings more than  years of industry experience in the development of vaccines and monoclonal antibody products to geovax dr guirakhoo is a former executivesenior director of sanofi pasteur as senior vice president research and development dr guirakhoo will play a leading role in the expansion of geovaxs product development pipeline and will be integral to collaborating on the development and implementation of a growth strategy to build upon geovaxs novel platform technology and expertise he will also contribute to the companys ongoing efforts to develop and commercialize its hiv and ebola vaccines we are thrilled that dr guirakhoo will be joining us said harriet robinson phd chief scientific officer at geovax there is substantial work to be done to successfully move our current vaccine programs forward and to build upon our technology platform we are fortunate to have a professional of dr guirakhoos caliber adding his talents to the effort it is a major milestone for the company to have dr guirakhoo joining our scientific team in a leadership role robert mcnally phd geovaxs president and ceo added dr guirakhoo will be a key member of our senior management team his extensive experience in vaccine development will be important to us as we embark on our strategy to accelerate our hiv vaccine candidate to pivotal clinical trials and as we make further progress toward clinical trials for our ebolamarburg vaccines and as we look to geovaxs future nothing is more critical than continuously building our capabilities and collective expertise with experienced scientific minds dr guirakhoos experience and intellectual curiosity will serve us well and i expect he will move quickly in the identification of highvalue areas into which we may expand our product development portfolio we welcome dr guirakhoo and look forward to his contributions i am truly excited to join geovaxs team not only to further accelerate its advanced clinical programs for an hiv vaccine which is the only cost effective way to eradicate this devastating disease especially in developing countries but also utilize its novel platform to develop other vaccines with high medical impact said farshad guirakhoo phd dr guirakhoo has served in senior management and scientific roles within the biotechnology industry with vaxess technologies hookipa biotech sanofi pasteur acambis inc and oravax inc he earned his phd in virology at the medical university of vienna vienna austria holds a msc degree in genetics from the international institute for biophysics and biochemistry of tehran university and a bsc degree in biology from the national university of iran he conducted his postdoctoral training at the medical university of vienna and at the national centers for disease control and prevention cdc division of vectorborne infectious diseases in his scientific career dr guirakhoo has filed over  patent applications and is authorcoauthor of more than  publications including book chapters in peerreviewed journals in  he was named as one of the  most influential people in vaccines about geovax geovax labs inc is a clinicalstage biotechnology company developing human vaccines against infectious diseases using its novel vaccine platform current development programs are focused on vaccines against ebola marburg and human immunodeficiency virus hiv geovax believes its technology and vaccine development expertise is wellsuited for a wide variety of human infectious diseases for which there is an unmet medical need and intends to pursue expansion of its product pipeline geovaxs vaccine platform supports production of noninfectious viruslike particles vlps from the cells of the person receiving the vaccine the production of vlps in the person being vaccinated mimics a natural infection stimulating both the humoral and cellular arms of the immune system to recognize prevent and control the target infection  should it appear clinical trials for geovaxs preventive hiv vaccines have been conducted by the nihsupported hiv vaccine trials network hvtn with funding from the national institute of allergy and infectious disease niaid overall geovaxs hiv vaccines in various doses and combinations have been tested in about  humans for more information go to wwwgeovaxcom forwardlooking statements certain statements in this document are forwardlooking statements within the meaning of the private securities litigation reform act these statements are based on managements current expectations and are subject to uncertainty and changes in circumstances actual results may differ materially from those included in these statements due to a variety of factors including whether geovax can develop and manufacture its vaccines with the desired characteristics in a timely manner geovaxs vaccines will be safe for human use geovaxs vaccines will effectively prevent hiv or ebola infection in humans vaccines will receive regulatory approvals necessary to be licensed and marketed geovax raises required capital to complete vaccine development there is development of competitive products that may be more effective or easier to use than geovaxs products geovax will be able to enter into favorable manufacturing and distribution agreements and other factors over which geovax has no control geovax assumes no obligation to update these forwardlooking statements and does not intend to do so more information about these factors is contained in geovaxs filings with the securities and exchange commission including those set forth at risk factors in geovaxs form k contact robert t mcnally phdgeovax labs inc help employers find you check out all the jobs and post your resume read at biospacecom related news geovax inc reports  second quarter financial results and provides corporate update csuite shuffle at quintiles q geovax inc receives grant from nih for hiv vaccine program pfizer pfe zoloft coinventor ken koe dies at  years of age geovax labs inc govxob dnamva vaccine elicits sustained antibody responses to hiv cook medical vp daughter die in plane crash geovax labs inc govxob reports financial results for the second quarter and first half  and provides clinical development update aeterna zentaris aezs shutters quebec city office and cfo steps down amid stock plunge and class action lawsuit geovax labs inc govxob announces enrollment completion for phase  clinical trial for hivaids therapeutic vaccine as merck kgaa mkgafpk restructures board and focuses on immunooncology announces new ceo please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • ibeat   • biotechpharma  personnel                 farshad guirakhoo phd joins geovax as senior vice president research and development  gurufocuscom farshad guirakhoo phd joins geovax as senior vice president research and development  gurufocuscom home homepage membership levels membership data coverage complete stock list founders message the book free trial screeners value screens allinone screener industry overview ben graham netnet undervalued predictable buffettmunger screener magic formula greenblatt historical low ps list historical low pb list peter lynch screen high short interest weekyy lows weekyy highs predictable companies sp  grid dividend stocks spin off list downloads  tools excel addin guruf manual of stocks™ download financial data download guru portfolios download stock pdfs download insider data api mobile app strategies performances buffettmunger undervalued predictable low ps low pb broadest owned most weighted gurus latest guru picks real time picks list of gurus personalize gurus portfolios scoreboard top  holdings view sector picks international picks aggregated portfolio consensus picks guru bargains hot picks industry trends geographic trend etfs options european shorting insiders all insiders ceo buyssales cfo buyssales insider cluster guruinsider double buys triple buyssales insider trends canadian insider dutch insider market market valuation economic data industry overview marketcapgdp valuation global market valuation shiller pe shiller pe by sectors buffett assets allocation by country usa australia canada china germany india japan uk more articles articles editors picks gurufocus research value ideas interviews with gurus top ranked value idea contest videos following authors submit articles writers wanted value contest winners submit articles online my articles conference value conference speakers locationvenue register after conference gathering free drinks tutorials tutorials  webinars faq contact us log in free signup log in day free trial subscribe free trial year refer a friend  earn  search compare search ▾ get day free trial my portfolios▾ portfolios overview create new portfolio portfolio contest my gurus▾ quick browse personalize my gurus premium gurus premium plus investors how to use gurufocus  tutorials what is in the gurufocus premium membership a diy guide on how to invest using guru strategies press releasearticles  bookmark print tweet bookmark name this page was added to your bookmark members only please sign up or log in first bookmark of this page has been deleted farshad guirakhoo phd joins geovax as senior vice president research and developmentoctober    about govx  scientific leadership team strengthened atlanta gamarketwired  oct    geovax labs inc otcqb govx a biotechnology company developing human vaccines using its novel platform technology announced today the appointment of farshad guirakhoo phd as senior vice president research and development dr guirakhoo is a worldrenowned virologist and brings more than  years of industry experience in the development of vaccines and monoclonal antibody products to geovax dr guirakhoo is a former executivesenior director of sanofi pasteur as senior vice president research and development dr guirakhoo will play a leading role in the expansion of geovaxs product development pipeline and will be integral to collaborating on the development and implementation of a growth strategy to build upon geovaxs novel platform technology and expertise he will also contribute to the companys ongoing efforts to develop and commercialize its hiv and ebola vaccines warning gurufocus has detected  warning signs with govx click here to check it out govx year financial datathe intrinsic value of govxpeter lynch chart of govxwe are thrilled that dr guirakhoo will be joining us said harriet robinson phd chief scientific officer at geovax there is substantial work to be done to successfully move our current vaccine programs forward and to build upon our technology platform we are fortunate to have a professional of dr guirakhoos caliber adding his talents to the effort it is a major milestone for the company to have dr guirakhoo joining our scientific team in a leadership role robert mcnally phd geovaxs president and ceo added dr guirakhoo will be a key member of our senior management team his extensive experience in vaccine development will be important to us as we embark on our strategy to accelerate our hiv vaccine candidate to pivotal clinical trials and as we make further progress toward clinical trials for our ebolamarburg vaccines and as we look to geovaxs future nothing is more critical than continuously building our capabilities and collective expertise with experienced scientific minds dr guirakhoos experience and intellectual curiosity will serve us well and i expect he will move quickly in the identification of highvalue areas into which we may expand our product development portfolio we welcome dr guirakhoo and look forward to his contributions i am truly excited to join geovaxs team not only to further accelerate its advanced clinical programs for an hiv vaccine which is the only cost effective way to eradicate this devastating disease especially in developing countries but also utilize its novel platform to develop other vaccines with high medical impact said farshad guirakhoo phd dr guirakhoo has served in senior management and scientific roles within the biotechnology industry with vaxess technologies hookipa biotech sanofi pasteur acambis inc and oravax inc he earned his phd in virology at the medical university of vienna vienna austria holds a msc degree in genetics from the international institute for biophysics and biochemistry of tehran university and a bsc degree in biology from the national university of iran he conducted his postdoctoral training at the medical university of vienna and at the national centers for disease control and prevention cdc division of vectorborne infectious diseases in his scientific career dr guirakhoo has filed over  patent applications and is authorcoauthor of more than  publications including book chapters in peerreviewed journals in  he was named as one of the  most influential people in vaccines about geovax geovax labs inc is a clinicalstage biotechnology company developing human vaccines against infectious diseases using its novel vaccine platform current development programs are focused on vaccines against ebola marburg and human immunodeficiency virus hiv geovax believes its technology and vaccine development expertise is wellsuited for a wide variety of human infectious diseases for which there is an unmet medical need and intends to pursue expansion of its product pipeline geovaxs vaccine platform supports production of noninfectious viruslike particles vlps from the cells of the person receiving the vaccine the production of vlps in the person being vaccinated mimics a natural infection stimulating both the humoral and cellular arms of the immune system to recognize prevent and control the target infection  should it appear  clinical trials for geovaxs preventive hiv vaccines have been conducted by the nihsupported hiv vaccine trials network hvtn with funding from the national institute of allergy and infectious disease niaid overall geovaxs hiv vaccines in various doses and combinations have been tested in about  humans for more information go to wwwgeovaxcom forwardlooking statements certain statements in this document are forwardlooking statements within the meaning of the private securities litigation reform act these statements are based on managements current expectations and are subject to uncertainty and changes in circumstances actual results may differ materially from those included in these statements due to a variety of factors including whether geovax can develop and manufacture its vaccines with the desired characteristics in a timely manner geovaxs vaccines will be safe for human use geovaxs vaccines will effectively prevent hiv or ebola infection in humans vaccines will receive regulatory approvals necessary to be licensed and marketed geovax raises required capital to complete vaccine development there is development of competitive products that may be more effective or easier to use than geovaxs products geovax will be able to enter into favorable manufacturing and distribution agreements and other factors over which geovax has no control geovax assumes no obligation to update these forwardlooking statements and does not intend to do so more information about these factors is contained in geovaxs filings with the securities and exchange commission including those set forth at risk factors in geovaxs form k contact robert t mcnally phd geovax labs inc  currently  rating   votes subscribe via email subscribe rss comments please leave your comment more gurufocus links latest guru picks value strategies warren buffett portfolio ben graham netnet real time picks buffettmunger screener aggregated portfolio undervalued predictable etfs options low ps companies insider trends year financials week lows interactive charts model portfolios dcf calculator rss feed monthly newsletters the allinone screener portfolio tracking tool gurufocus has detected  warning signs with geovax labs inc govx more than  people have already joined gurufocus to track the stocks they follow and exchange investment ideas →performances of the stocks mentioned by press release →user generated screeners gurufocusipo dateculpelprojected fcfp ebitdaculpelprojected fcfp trebitrharmelinkdividend champions with weeklyzebulonminstandardsraelpbarkerbig dividend stockshsaabjulyraelrael →govx price chart→guru newsfpa capital fund nd quarter  commentary by holly lafonchevron up slightly after reporting ndquarter earnings by sydnee gatewoodbrewing a solid rdquarter earnings report by ben reynoldsbluechip stocks in focus consolidated edison by ben reynolds→value ideasironwood investment management llc buys pinnacle financial partners inc tahoe resources inc invacare corp sells ultratech inc bnc bancorp shoe carnival inc by insiderintuitive surgical inc isrg president  ceo gary s guthart sold  million of shares by insidertweedy browne comments on akzo by holly lafontweedy browne comments on nestle by holly lafon→guru interviewspodcast episode  healthcare investing pro mindy perry by holly lafonpodcast episode  interview with legendary investor jeanmarie eveillard by holly lafon questions with the founder of wayundervaluedcom by pj pahygiannisgurufocus interview orbimed guru sam isaly on investing in new era of healthcare by holly lafon→top ranked articlessome thoughts on holding cash by the science of hittingberkshire and blue chip stamps by the science of hittingmohnish pabrai crushing it with  bestperforming car companies ferrari and fiat by holly lafonsome signs of competitive pressures in credit by the science of hitting →you may also likegeovax announces filing of investigational new drug application for hiv human clinical trialgeovax announces filing of investigational new drug application for hiv human clinical trialgeovax announces filing of investigational new drug application for hiv human clinical trialgeovax awarded nih grant for hiv vaccine programgeovax discusses zika vaccine development at american society for virologys th annual meeting select portfolios create a new portfolio why you are interested your selection and notes will be stored in your portfolio login to add portfolio get wordpress plugins for easy affiliate links on stock tickers and guru names  earn affiliate commissions by embedding gurufocus charts gurufocus affiliate program earn up to  per referral  learn more home  about   jobs   advertise    site map    term of use    privacy policy     rss    mobile app     email alerts    referral program    affiliate program    faq    contact us      gurufocuscom llc all rights reserved disclaimers gurufocuscom is not operated by a broker a dealer or a registered investment adviser under no circumstances does any information posted on gurufocuscom represent a recommendation to buy or sell a security the information on this site and in its related newsletters is not intended to be nor does it constitute investment advice or recommendations the gurus may buy and sell securities before and after any particular article and report and information herein is published with respect to the securities discussed in any article and report posted herein in no event shall gurufocuscom be liable to any member guest or third party for any damages of any kind arising out of the use of any content or other material published or available on gurufocuscom or relating to the use of or inability to use gurufocuscom or any content including without limitation any investment losses lost profits lost opportunity special incidental indirect consequential or punitive damages past performance is a poor indicator of future performance the information on this site and in its related newsletters is not intended to be nor does it constitute investment advice or recommendations the information on this site is in no way guaranteed for completeness accuracy or in any other way the gurus listed in this website are not affiliated with gurufocuscom llc stock quotes provided by interactive data fundamental company data provided by morningstar updated daily gf chat  × manage bookmarks close feedback farshad guirakhoo phd joins geovax as senior vice president research and development  hiv aids vaccine research geovax  recent news recent news latest geovax news home home this is where you can find all the blog posts throughout the site categories categories displays a list of categories from this blog tags tags displays a list of tags that have been used in the blog search farshad guirakhoo phd joins geovax as senior vice president research and development font size larger smaller hits  print bookmark  oct    scientific leadership team strengthened   geovax labs inc otcqb govx a biotechnology company developing human vaccines using its novel platform technology announced today the appointment of farshad guirakhoo phd as senior vice president research and development dr guirakhoo is a worldrenowned virologist and brings more than  years of industry experience in the development of vaccines and monoclonal antibody products to geovax dr guirakhoo is a former executivesenior director of sanofi pasteur as senior vice president research and development dr guirakhoo will play a leading role in the expansion of geovax’s product development pipeline and will be integral to collaborating on the development and implementation of a growth strategy to build upon geovax’s novel platform technology and expertise he will also contribute to the company’s ongoing efforts to develop and commercialize its hiv and ebola vaccines “we are thrilled that dr guirakhoo will be joining us” said harriet robinson phd chief scientific officer at geovax “there is substantial work to be done to successfully move our current vaccine programs forward and to build upon our technology platform we are fortunate to have a professional of dr guirakhoo’s caliber adding his talents to the effort it is a major milestone for the company to have dr guirakhoo joining our scientific team in a leadership role” robert mcnally phd geovax’s president and ceo added “dr guirakhoo will be a key member of our senior management team his extensive experience in vaccine development will be important to us as we embark on our strategy to accelerate our hiv vaccine candidate to pivotal clinical trials and as we make further progress toward clinical trials for our ebolamarburg vaccines and as we look to geovax’s future nothing is more critical than continuously building our capabilities and collective expertise with experienced scientific minds dr guirakhoo’s experience and intellectual curiosity will serve us well and i expect he will move quickly in the identification of highvalue areas into which we may expand our product development portfolio we welcome dr guirakhoo and look forward to his contributions” “i am truly excited to join geovax’s team not only to further accelerate its advanced clinical programs for an hiv vaccine which is the only cost effective way to eradicate this devastating disease especially in developing countries but also utilize its novel platform to develop other vaccines with high medical impact” said farshad guirakhoo phd dr guirakhoo has served in senior management and scientific roles within the biotechnology industry with vaxess technologies hookipa biotech sanofi pasteur acambis inc and oravax inc he earned his phd in virology at the medical university of vienna vienna austria holds a msc degree in genetics from the international institute for biophysics and biochemistry of tehran university and a bsc degree in biology from the national university of iran he conducted his postdoctoral training at the medical university of vienna and at the national centers for disease control and prevention cdc division of vectorborne infectious diseases in his scientific career dr guirakhoo has filed over  patent applications and is authorcoauthor of more than  publications including book chapters in peerreviewed journals in  he was named as one of the  most influential people in vaccines  about geovax geovax labs inc is a clinicalstage biotechnology company developing human vaccines against infectious diseases using its novel vaccine platform current development programs are focused on vaccines against ebola marburg and human immunodeficiency virus hiv geovax believes its technology and vaccine development expertise is wellsuited for a wide variety of human infectious diseases for which there is an unmet medical need and intends to pursue expansion of its product pipeline geovax’s vaccine platform supports production of noninfectious viruslike particles vlps from the cells of the person receiving the vaccine the production of vlps in the person being vaccinated mimics a natural infection stimulating both the humoral and cellular arms of the immune system to recognize prevent and control the target infection  should it appear clinical trials for geovax’s preventive hiv vaccines have been conducted by the nihsupported hiv vaccine trials network hvtn with funding from the national institute of allergy and infectious disease niaid overall geovax’s hiv vaccines in various doses and combinations have been tested in about  humans for more information go to wwwgeovaxcom forwardlooking statements certain statements in this document are forwardlooking statements within the meaning of the private securities litigation reform act these statements are based on managements current expectations and are subject to uncertainty and changes in circumstances actual results may differ materially from those included in these statements due to a variety of factors including whether geovax can develop and manufacture its vaccines with the desired characteristics in a timely manner geovaxs vaccines will be safe for human use geovaxs vaccines will effectively prevent hiv or ebola infection in humans vaccines will receive regulatory approvals necessary to be licensed and marketed geovax raises required capital to complete vaccine development there is development of competitive products that may be more effective or easier to use than geovaxs products geovax will be able to enter into favorable manufacturing and distribution agreements and other factors over which geovax has no control geovax assumes no obligation to update these forwardlooking statements and does not intend to do so more information about these factors is contained in geovaxs filings with the securities and exchange commission including those set forth at risk factors in geovaxs form k   last modified on tuesday  november  geovax ebola vaccine proven effective in rodent mo geovax reports  third quarter financial result farshad guirakhoo phd joins geovax as senior vice president research and development news home advertising board and executive moves energy health care hedge funds m  a private equity technology powered by farshad guirakhoo phd joins geovax as senior vice president research and development email linkedin facebook google tweet reddit permalink oct    marketwired board and executive moves geovax labs inc otcqb govx a biotechnology company developing human vaccines using its novel platform technology announced today the appointment of farshad guirakhoo phd as senior vice president research and development dr guirakhoo is a worldrenowned virologist and brings more than  years of industry experience in the development of vaccines and monoclonal antibody products to geovax dr guirakhoo is a former executivesenior director of sanofi pasteuras senior vice p sign up for unrestricted access to  subscription services by signing up you agree to our terms of use privacy policy and the lexisnexis terms  conditions already have an account click here to login relsci news  alerts gets you  free articles a month from top subscription outlets like the financial times new york times and washington post competitive business intelligence through daily data updates custom feeds on target highvalue individuals companies industries and topics delivered straight to your inbox related news feeds geovax labs inc biotechnology board and executive moves in biotechnology alumni of university of vienna create your own custom news feed mentioned entities farshad guirakhoo sanofi pasteur inc vienna university of economics  business administration geovax labs inc robert t mcnally harriet l robinson see how you can reach these people and organizations youve found a premium relsci pro feature connect to individuals and organizations in this story upgrade to relsci pro to easily sync your contacts and see how you can reach the people and organizations featured in this article start my free trial ➤ still not convinced check out our full listing of features here not now are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤ login  evaluate retrieving data you are a  user the feature you are trying to access  subscribers please register to access this feature or log in if you are a subscriber or if you have already registered please click the following link to register and submit an upgrade request so that a member of our sales team can contact you to discuss your requirements register and upgrade please click the request upgrade button to log your details so that a member of our sales team can contact you to discuss your additional requirements your request to access this feature is pending you have already logged a callback request a member of our team will contact you to discuss your access level view my contact details   this feature is not yet available we have already attempted to contact you following your recent request we will try and call you again shortly but in the meantime please check that your contact details are correct and up to date or if you prefer please contact us view my contact details   contact us retrieving ep vantage brings a fresh view on pharma and biotech with incisive daily analysis powered by evaluate ltd you are a subscriber to the full evaluate ltd service click here to login to the subscribers welcome page        no i do not want to log in now dont remind me again you are currently accessing our secondary server although the site contains up to date data some features are unfortunately not available on the secondary server we apologise for any inconvenience this may cause close ecommerce support if you would prefer to speak to a member of our sales team please call us on     alternatively if you are experiencing problems with an existing order a member of our support team will be happy to assist you call     telephone lines are open mon  fri am  pm london time alternatively send an email to chrissiepennockevaluategroupcom close shopping cart fetching cart contents please wait please register your details with us to complete your purchase or click login if you have already registered with us     close report summary retrieving report details share with a colleague     show report description this report has already been purchased and is available to view now or you may purchase the report again for the latest data you have already purchased this report but a problem is preventing you from accessing the information it contains before calling a member of our support team please attempt to regenerate your report again from your purchase history page add this item to my basket or regenerate for free this item has already been added to your cart regenerating content    please complete the fields below recipients email    required your email    required your name    required optional message sending email   an email has been successfully sent return to report summary failed to send return to report summary failed to retrieve further details for this product the item has successfully been added to your cart your selected reports will remain in your cart for  days you have succeeded in buying the reports however you havent generated your reports yet please go to purchase history to generate your ordered reports now site maintenance planned the website will be unavailable on thursday  april from pm for routine maintenance please save your work and log out before then remind me later x got it farshad guirakhoo joins geovax as senior vice president research and development farshad guirakhoo joins geovax as senior vice president research and development oct north america  research  vaccines us biotechnology firm strengthens its scientific leadership team geovax labs a biotechnology company developing human vaccines using its novel platform technology says farshad guirakhoo has joined the firm as senior vice president research and development guirakhoo is a worldrenowned virologist and brings more than  years of experience in the development of vaccines and monoclonal antibody products to geovax he is a former executivesenior director of sanofi pasteur in his new role guirakhoo will play a leading role in the expansion of geovaxs product development pipeline and will be integral to collaborating on the development and implementation of a growth strategy to build upon geovaxs novel platform technology and expertise he will also contribute to the companys ongoing efforts to develop and commercialise its hiv and ebola vaccines we are thrilled that dr guirakhoo will be joining us said harriet robinson chief scientific officer at geovax there is substantial work to be done to successfully move our current vaccine programmes forward and to build upon our technology platform we are fortunate to have a professional of dr guirakhoos calibre adding his talents to the effort dr guirakhoo has held senior management and scientific roles within the biotechnology industry with vaxess technologies hookipa biotech sanofi pasteur acambis and oravax companies geovax labs subscriber sign in email password why subscribe related articles zika outbreak gives rise to global fears geovax launches second clinical site to test hiv vaccine sanofi to acquire protein science move toward cellbased manufacturing signals opening in vaccine market antibacterial drugs market will hit  billion by  says gbi research catalent biologics announces agreement with moderna therapeutics fda approves vaccine to prevent cholera for travellers meningococcal vaccines market set to approach bn by  says globaldata protein sciences sinergium biotech and mundo sano form zika vaccine partnership inovio to buy needlefree injection technology from bioject medical technologies for usm new tobaccobased flu vaccine offers promising alternative to eggbased versions says globaldata analyst related press releases catalent biologics collaborates with path malaria vaccine initiative cancer vaccines market will soar to  billion by  says gbi research fda research to help speed development of zika virus vaccines and therapeutics related jobs vbi vaccines appoints dr francisco diazmitoma as chief medical officer novavax announces management promotion paragon bioservices appoints bill thomas as chief technology officer novavax makes management promotions farshad guirakhoo phd joins geovax as senior vice president research and developmenthomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets closedsp  dow  nasdaq listenwho is the face of pro baseballyahoo finances dan roberts and myles udland debate the business of baseballfarshad guirakhoo phd joins geovax as senior vice president research and developmentmarketwiredoctober  reblogsharetweetshareatlanta gamarketwired  oct    geovax labs inc  otcqb  govx  a biotechnology company developing human vaccines using its novel platform technology announced today the appointment of farshad guirakhoo phd as senior vice president research and development dr guirakhoo is a worldrenowned virologist and brings more than  years of industry experience in the development of vaccines and monoclonal antibody products to geovax dr guirakhoo is a former executivesenior director of sanofi pasteuras senior vice president research and development dr guirakhoo will play a leading role in the expansion of geovaxs product development pipeline and will be integral to collaborating on the development and implementation of a growth strategy to build upon geovaxs novel platform technology and expertise he will also contribute to the companys ongoing efforts to develop and commercialize its hiv and ebola vaccineswe are thrilled that dr guirakhoo will be joining us said harriet robinson phd chief scientific officer at geovax there is substantial work to be done to successfully move our current vaccine programs forward and to build upon our technology platform we are fortunate to have a professional of dr guirakhoos caliber adding his talents to the effort it is a major milestone for the company to have dr guirakhoo joining our scientific team in a leadership rolerobert mcnally phd geovaxs president and ceo added dr guirakhoo will be a key member of our senior management team his extensive experience in vaccine development will be important to us as we embark on our strategy to accelerate our hiv vaccine candidate to pivotal clinical trials and as we make further progress toward clinical trials for our ebolamarburg vaccines and as we look to geovaxs future nothing is more critical than continuously building our capabilities and collective expertise with experienced scientific minds dr guirakhoos experience and intellectual curiosity will serve us well and i expect he will move quickly in the identification of highvalue areas into which we may expand our product development portfolio we welcome dr guirakhoo and look forward to his contributionsi am truly excited to join geovaxs team not only to further accelerate its advanced clinical programs for an hiv vaccine which is the only cost effective way to eradicate this devastating disease especially in developing countries but also utilize its novel platform to develop other vaccines with high medical impact said farshad guirakhoo phddr guirakhoo has served in senior management and scientific roles within the biotechnology industry with vaxess technologies hookipa biotech sanofi pasteur acambis inc and oravax inc he earned his phd in virology at the medical university of vienna vienna austria holds a msc degree in genetics from the international institute for biophysics and biochemistry of tehran university and a bsc degree in biology from the national university of iran he conducted his postdoctoral training at the medical university of vienna and at the national centers for disease control and prevention cdc division of vectorborne infectious diseases in his scientific career dr guirakhoo has filed over  patent applications and is authorcoauthor of more than  publications including book chapters in peerreviewed journals in  he was named as one of the  most influential people in vaccinesabout geovaxgeovax labs inc is a clinicalstage biotechnology company developing human vaccines against infectious diseases using its novel vaccine platform current development programs are focused on vaccines against ebola marburg and human immunodeficiency virus hiv geovax believes its technology and vaccine development expertise is wellsuited for a wide variety of human infectious diseases for which there is an unmet medical need and intends to pursue expansion of its product pipelinegeovaxs vaccine platform supports production of noninfectious viruslike particles vlps from the cells of the person receiving the vaccine the production of vlps in the person being vaccinated mimics a natural infection stimulating both the humoral and cellular arms of the immune system to recognize prevent and control the target infection  should it appear read moreclinical trials for geovaxs preventive hiv vaccines have been conducted by the nihsupported hiv vaccine trials network hvtn with funding from the national institute of allergy and infectious disease niaid overall geovaxs hiv vaccines in various doses and combinations have been tested in about  humans for more information go to wwwgeovaxcomforwardlooking statementscertain statements in this document are forwardlooking statements within the meaning of the private securities litigation reform act these statements are based on managements current expectations and are subject to uncertainty and changes in circumstances actual results may differ materially from those included in these statements due to a variety of factors including whether geovax can develop and manufacture its vaccines with the desired characteristics in a timely manner geovaxs vaccines will be safe for human use geovaxs vaccines will effectively prevent hiv or ebola infection in humans vaccines will receive regulatory approvals necessary to be licensed and marketed geovax raises required capital to complete vaccine development there is development of competitive products that may be more effective or easier to use than geovaxs products geovax will be able to enter into favorable manufacturing and distribution agreements and other factors over which geovax has no control geovax assumes no obligation to update these forwardlooking statements and does not intend to do so more information about these factors is contained in geovaxs filings with the securities and exchange commission including those set forth at risk factors in geovaxs form kreblogsharetweetsharerecently viewedyour list is emptywhat to read nexttrump divorce former nfl cheerleader and florida state attorney split over us presidentthe telegraphthis will be in everyones household by banyan hillsponsoredamazons alexa boss says the ultimate goal is to reinvent the star trek computerbusiness insidertrump to cops please dont be too nice while arresting thugs and dont worry about their heads when you toss them in the paddy wagonbusiness insiderthe two pizza rule is a secret to productive meetings that helped amazon ceo jeff bezos become one of the worlds richest menbusiness insiderengineer finds pattern makes millions in stocksmoney morningsponsoredwells fargo faces angry questions after new sales abuses uncoveredreuterschevron and exxon mobil have a tough path ahead nyse traderyahoo finance videostocks mixed after heavy earnings weektrunk club making sense of styletrunk clubsponsoredtrump names john f kelly new chief of staff reince priebus outcnbcapnewsbreak yellowstone park cracks down on sex harassmentassociated pressthe real reason overseas manufacturing is coming to americayahoo financehuman barbie takes off make up drs are stunnedkiwi reportsponsoredmy bullish view on stocks hasnt changed one iota nyse traderyahoo finance videoblue apron bullish calls not all theyre cooked up to betrump vowing gang crackdown urges cops ‘don’t be too nice’harvey trump advocates torture so did hitler trump wants to register all members of a specific religion so did hitler trump encourages his supporters to commit acts of violence against those who disagee with him so did hitler trump is a pompous malicious selfaggrandizing megalomaniac who tries to discredit and marginalize the free press and open access to information so was hitler if it walks like hitler and it talks like hitler its far more likely that the donald is a wannabe hitler than a duckjoin the conversation  k